US Start-Up Phlow Receives Further Capital Injection To Fund Essential Medicines
Cash Will Be Used For Multiple Key Initiatives
Executive Summary
Fresh from its $812m government contract to help prevent shortages of essential medicines and shield the US market from global competition, domestic start-up Phlow Corporation has received further financial backing.
You may also be interested in...
‘Critical To Bring Back Domestic Manufacturing Of Key Essentials’ Insists Phlow CEO
In an exclusive interview with Generics Bulletin, Phlow Corp CEO Eric Edwards has criticized the growing list of drug shortages in the US. He outlined the government-backed company’s objective of tackling drug shortages and supply chain vulnerabilities, to create a national stockpile of essential medicines.
Civica Partners With Phlow To Build $125m Injectables Facility In US
Lauding a “dream come true,” Civica has announced plans to build its own injectables manufacturing facility via a strategic partnership with fellow public health firm Phlow Corporation.
AAM Urges US Senate To Back Domestic Production
While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”